Clinical trials: Liver Function
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
- Trial name
- NCT00421044
- Testing
- Patupilone/EPO906
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
HCV Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.
- Trial name
- NCT02402452
- Testing
- Voxilaprevir
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatic Impairment
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
The primary purpose of this open-label study is to characterize the plasma pharmacokinetics (PK) of manogepix (active moiety of fosmanogepix) in participants with varying degrees of hepatic function following administration of a…
- Trial name
- NCT05582187
- Testing
- Fosmanogepix
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Liver Cirrhosis
The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics and pharmacodynamics of recombinant human thrombopoietin in the patients with different degree of liver function impairment according Child- Pugh…
- Trial name
- NCT03673215
- Testing
- Recombinant human thrombopoietin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
The primary purpose of the study is to compare the PK of a single dose of brensocatib in participants with hepatic impairment to that in matched healthy control participants with normal hepatic function.
- Trial name
- NCT05517525
- Testing
- Brensocatib
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Insmed Incorporated
Hepatic Impairment (HI)
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver…
- Trial name
- NCT07324616
- Testing
- EDG-7500
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Edgewise Therapeutics, Inc.
Moderate Hepatic Impairment, Severe Hepatic Impairment
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Lorlatinib) in health participants.
- Conditions
- Moderate Hepatic Impairment, Severe Hepatic Impairment, Healthy Volunteers
- Trial name
- NCT05224609
- Testing
- Lorlatinib
- Where
- 3 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Pfizer
Moderate Hepatic Impairment
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function
The purpose of this study is to assess the pharmacokinetics (what the body does to the medication), safety and tolerability of TMC207 and its N-monodesmethyl metabolite (M2) in healthy participants and in patients with moderate…
- Trial name
- NCT01012284
- Testing
- TMC207
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Hepatic Carcinoma
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma in poor liver function, also Progress Free Survival (PFS) and Over Survival (OS) will be…
- Trial name
- NCT02352935
- Testing
- NanoKnife LEDC System
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Cholecystitis, Acute, Cholecystitis, Chronic
BDD With UDCA Therapy After Laparoscopic Cholecystectomy
Prospective Study for the Effects of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycolic Acid Therapy on Liver Function and Quality of Life After Laparoscopic Cholecystectomy Primary endpoint: peak level of postoperative AST…
- Trial name
- BULQ-LC (NCT03578055)
- Testing
- BDD with UDCA
- Where
- South Korea
- Volunteers
- 172 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Non-Alcoholic Fatty Liver Disease
The Effect of Coenzyme Q10 on Endothelial, Vascular and Myocardial Function
Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients…
- Trial name
- NCT05941910
- Testing
- Q10
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Attikon Hospital
Chronic Hepatitis, Chronic Hepatitis C
The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients
The investigators will evaluate the efficacy of high dose vitamin C in chronic hepatitis patients whose serum liver enzymes are elevated more than upper limit.
- Conditions
- Chronic Hepatitis, Chronic Hepatitis C, Chronic Alcoholic Hepatitis
- Trial name
- NCT01413360
- Testing
- High dose vitamin C
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Seoul National University Hospital
Non-Alcoholic Fatty Liver Disease, Obesity
Effect of L-Citrulline Supplementation on NAFLD in Adolescents With Obesity
One of the comorbidities of obesity is nonalcoholic fatty liver disease (NAFLD). L-citrulline is a non-protein amino acid that has shown positive effects on the degree of fat retention and metabolic profile in NAFLD.
- Trial name
- NCT04871360
- Testing
- L-Citrulline supplement, Carboxymethyl cellulose supplement
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Universidad de Guanajuato
Liver Fibrosis
Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal…
- Trial name
- NCT07394309
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hip Osteoarthritis, Osteoarthritis, Hip
Gluteal Sling Release on Gluteal Dysfunction After in Primary Total Hip Arthroplasty
This study investigates the effects of gluteal sling release during total hip arthroplasty (THA) on gluteal muscle function and hip joint performance.
- Conditions
- Hip Osteoarthritis, Osteoarthritis, Hip, Gluteus Maximus Muscle Atrophy, Muscle Weakness Condition
- Trial name
- NCT06850155
- Testing
- Sling release, Sling release and repair
- Where
- Turkey (Türkiye)
- Volunteers
- 144 people
- Sponsor
- Ankara City Hospital Bilkent
Non-alcoholic Steato-hepatitis
: Identification of Non-alcoholic Steato-hepatitis Cases in a Sample of Type 2 Diabetes Patients, with a Disruption of the Liver Function Tests, At the Pointe-à-Pitre University Hospital
Non-alcoholic steatohepatitis (NASH) develops on insulin resistance, especially in patients with carbohydrate tolerance. NASH may progress to more extensive fibrosis, including cirrhosis, but also to HCC with or without cirrhosis…
- Trial name
- STEATOGWAD (NCT06738810)
- Testing
- Fibrotest-actitest/NASHtest
- Where
- Guadeloupe
- Volunteers
- 103 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Hepatitis B, Chronic
Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients
Previous studies indicated that Granulocyte Macrophage-colony Stimulating Factor (GM-CSF) could improve survival rate in patients with acute liver failure and obtain higher HBsAg seroconversion rate when in combination with…
- Trial name
- NCT03164889
- Testing
- Granulocyte Macrophage-colony Stimulating Factor, Entecavir
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing 302 Hospital
Liver Cancer, Adult
Liver Function Investigation With SPECT
This is a Phase 1 pilot study to assess feasibility and utility of 99mTc-mebrofenin hepatobiliary scintigraphy for measurement of functional liver change due to radiotherapy.
- Trial name
- LiverINSPECT (NCT02967848)
- Testing
- 99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green, Liver Elasticity
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Royal North Shore Hospital
Hepatic Impairment
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Study AG120-C-012 is a Phase 1, open-label, single-dose study designed to evaluate the PK, safety, and tolerability of a single 500 mg AG-120 (Ivosidenib) dose in subjects with mild or moderate hepatic impairment (HI) compared to…
- Trial name
- NCT03282513
- Testing
- AG-120 (Ivosidenib)
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Influenza Type A, Influenza Type B
To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects
This study aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of ADC189 in subjects with hepatic impairment compared with subjects with normal hepatic function.
- Trial name
- NCT06485401
- Testing
- ADC189
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiaxing AnDiCon Biotech Co.,Ltd